Abstract

Introduction/BackgroundStandard therapy for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months includes PARPi maintenance if disease responds to platinum-based chemotherapy. ANITA (NCT03598270) evaluated combining atezolizumab with platinum-based...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
#525 Impact of BRCA mutation status on efficacy of atezolizumab combined with platinum-based chemotherapy and maintenance niraparib for late-relapsing recurrent ovarian cancer: subgroup analysis of the ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial
Frédéric Selle ... Philippe Follana
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. 34
Frédéric Selle, et. al.Frédéric Selle ... Philippe Follana
01 Mar 2024
#928 Subgroup analysis by chemotherapy regimen in the ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial evaluating atezolizumab combined with a platinum doublet and maintenance niraparib for late-relapsing ovarian cancer
Florian Heitz ... Luisa Sánchez-Lorenzo
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. 34
Florian Heitz, et. al.Florian Heitz ... Luisa Sánchez-Lorenzo
01 Mar 2024
ENGOT-Ov41/GEICO-69-O/ANITA trial: A phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or peritoneal cancer (OC) and platinum treatment-free interval (TFIp) >6 months.
Antonio González-Martín ... Florian Heitz
Journal of Clinical Oncology | VOL. 37
Antonio González-Martín, et. al.Antonio González-Martín ... Florian Heitz
20 May 2019
Oncologic outcomes of secondary cytoreductive surgery in the era of poly (ADP-ribose) polymerase inhibitors maintenance (549)
Sarah Ehmann ... Rachel Grisham
Gynecologic oncology | VOL. 166
Sarah Ehmann, et. al.Sarah Ehmann ... Rachel Grisham
01 Aug 2022
View more papers

More From: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Paper Title
Journal
Date
Author
Predicting outcomes in malignant ovarian germ cell tumors using the modified International Germ Cell Cancer Collaborative Group classification system
Xinyue Zhang ... Jiaxin Yang
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Xinyue Zhang, et. al.Xinyue Zhang ... Jiaxin Yang
16 Jul 2024
Oncological outcomes after laparotomic, laparoscopic, and robot-assisted laparoscopic staging for early high–intermediate or high-risk endometrial cancer
Ruben C G Koek ... Cornelis G Gerestein
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Ruben C G Koek, et. al.Ruben C G Koek ... Cornelis G Gerestein
16 Jul 2024
Predictive factors for adnexal involvement in endometrial cancer FIGO stage IIIA
Giorgia Dinoi ... Francesco Fanfani
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Giorgia Dinoi, et. al.Giorgia Dinoi ... Francesco Fanfani
13 Jul 2024
Role of V-Y flap reconstruction in vulvar cancer patients: multicenter retrospective study
Violante Di Donato ... Giorgio Bogani
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Violante Di Donato, et. al.Violante Di Donato ... Giorgio Bogani
13 Jul 2024
View more papers